Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02139930
Other study ID # U54 DA031659-P2
Secondary ID U54DA031659
Status Completed
Phase N/A
First received
Last updated
Start date September 2014
Est. completion date March 14, 2017

Study information

Verified date August 2018
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main goal of this project is to compare two different approaches to reducing levels of nicotine in cigarettes: an immediate reduction in nicotine content in cigarettes to non-addictive levels or a gradual reduction in nicotine content in cigarettes to non-addictive levels. These two approaches will then be contrasted to a group that continues to smoke cigarettes with nicotine content similar to conventional cigarettes.


Description:

This project will be conducted to compare product use patterns and biomarkers of exposure between smokers who are assigned to a) gradual reduction in reduced nicotine content (RNC) cigarettes; b) immediate reduction to very low nicotine content (VLNC) cigarettes or c) normal nicotine content (NNC) cigarettes. The outcomes from this study will provide information on different approaches to reducing levels of nicotine in cigarettes and will determine the approach with the most optimal outcomes taking into account the balance between overall risk reduction (possibly maximized by abrupt switching) and compliance and acceptability (possibly maximized by gradual reduction of RNC cigarettes).


Recruitment information / eligibility

Status Completed
Enrollment 1250
Est. completion date March 14, 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age 18+

2. Daily smokers who smoke an average of at least five cigarettes per day for at least 1 year

3. Breath CO levels > 8 ppm (if = 8 ppm, then NicAlert Strip level must indicate regular smoking)

Exclusion Criteria:

1. Planned quit date in the next 30 days

2. Currently seeking treatment for smoking cessation

3. Currently using nicotine replacement therapies or other pharmacotherapies as cessation aid (non-cessation intermittent use acceptable)

4. A quit attempt in the past 30 days resulting in greater than 3 days of abstinence

5. Using other tobacco products or e-cigarettes more than 9 days in the past 30 days

6. Significant unstable medical conditions (Any significant change in a serious medical condition occurring during the past 3 months including, cardiovascular disease, COPD, and cancer, as determined by the licensed medical professional at each site)

7. Unstable psychiatric conditions (Any significant change in psychiatric symptoms during the past 3 months as determined by the licensed medical professional at each site)

8. Schizophrenia and schizoaffective disorder

9. Psychiatric medication changes (e.g., new prescriptions, changes in dosages, or discontinuation of medications) in the past 3 months that was a result of negative changes in symptoms.

10. Positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP

1. Marijuana will be tested for but will not be an exclusionary criterion.

2. Participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded.

3. Participants failing the toxicology screen will be allowed to re-screen once.

11. Blood alcohol level > 0.01

a. Participants failing the blood alcohol screen will be allowed to re-screen once.

12. Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks per day (female/male))

13. Pregnant, trying to become pregnant or breastfeeding

14. Predominant use of 'roll your own cigarettes'

15. CO reading >80 ppm

16. Systolic BP greater than or equal to 160

a. Participants failing for blood pressure will be allowed to re-screen once.

17. Diastolic BP greater than or equal to 100

a. Participants failing for blood pressure will be allowed to re-screen once.

18. Systolic BP below 90 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)

a. Participants failing for blood pressure will be allowed to re-screen once.

19. Diastolic BP below 50 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)

a. Participants failing for blood pressure will be allowed to re-screen once.

20. Heart rate greater than or equal to 105 bpm

a. Participants failing for heart rate will be allowed to re-screen once.

21. Heart rate lower than 45 bpm and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)

a. Participants failing for heart rate will be allowed to re-screen once.

22. Indicating any suicidal ideation in the past month, suicide attempts in the past 5 years (if within past 5 to 10 years, requires physician approval), or score of >4 on the MINI suicide subscale

23. Household member enrolled in the study concurrently.

24. Inability to independently read and comprehend the consent form and other written study materials and measures because participants are required to complete parts of the protocol at home independently.

25. Participated in prior study that involved reduced nicotine content cigarettes.

26. Having participated in a research study during the past three months in a study that would impact baseline smoking or response to study products.

27. Currently taking the following anticonvulsant medications:

1. Phenytoin [Brand Name: Dilantin]

2. Carbamazepine [Brand Name: Tegretol, Carbatrol, Equetro, Epitol]

3. Oxcarbazepine [Brand Name: Trileptal]

4. Primidone [Brand Name: Mysoline]

5. Phenobarbital

28. Currently taking the following medication:

1. Bendamustine (Treanda)

2. Clopidogrel (Plavix)

3. Clozapine (Clozaril, FazaClo)

4. Erlotinib (Tarceva)

5. Flecainide (Tambocor)

6. Fluvoxamine (Luvox)

7. Irinotecan (Camptosar)

8. Olanzapine (Zyprexa)

9. Ropinirole (Requip)

10. Tacrine (Cognex)

11. Theophylline (Theo Dur, etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Normal Nicotine Control Group
Participants will smoke experimental cigarettes for a period of 20-weeks.
Immediate Nicotine Reduction Group
Participants will smoke experimental cigarettes for a period of 20-weeks.
Gradual Nicotine Reduction Group
Participants will smoke experimental cigarettes for a period of 20-weeks.

Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland
United States University of Minnesota Medical School Duluth Duluth Minnesota
United States Duke University Durham North Carolina
United States Oregon Research Institute Eugene Oregon
United States MDAnderson Cancer Center Houston Texas
United States University of Minnesota Minneapolis Minnesota
United States University of Pennsylvania Philadelphia Pennsylvania
United States Mayo Clinic Phoenix Arizona
United States University of California San Francisco San Francisco California
United States Moffitt Cancer Center Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University Health Sciences National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicant exposure pattern: Expired air carbon monoxide Between group comparison of expired air carbon monoxide (CO) values at week 20 using baseline CO values as a covariate. 20-week treatment period
Primary Toxicant exposure pattern: Urinary phenanthrene tetroal (Phe) Between group comparison of urinary phenanthrene tetroal values at week 20 using baseline values as a covariate. 20-week treatment period
Primary Toxicant exposure pattern: Urinary mercapturic acids of acrolein Between group comparison of urinary mercapturic acid level at week 20 using baseline values as a covariate. 20-week treatment period
Secondary Nicotine exposure: Total nicotine equivalents (TNE) Between group comparison of urinary total nicotine equivalents at week 20 using baseline values as a covariate. End of treatment (Week 20)
Secondary Other toxicant exposure: Tobacco specific nitrosamines-Total NNAL and NNN Between group comparison of urinary total NNAL and NNN levels at week 20 using baseline values as a covariate. End of treatment (Week 20)
Secondary Effect biomarker: C-Reactive protein-high sensitivity as an inflammation biomarker Between group comparison of C-Reactive protein levels in serum at week 20 using baseline values as a covariate. End of treatment (Week 20)
Secondary Measure of acceptability: Retention in study Between group comparison of early termination from the study. End of treatment (Week 20)
Secondary Measure of acceptability: Non-compliance Between group comparison of use of non-study tobacco products. End of treatment (Week 20)
Secondary Effect biomarker: 8-epi-PGF2a as a biomarker for oxidative stress Between group comparison of 8-epi-PGF2a at week 20 using baseline values as a covariate. End of treatment (Week 20)
Secondary Effect biomarker: White blood cells count as inflammation biomarker Between group comparison of white blood cell count at week 20 using baseline values as a covariate. End of treatment (Week 20)
Secondary Nicotine exposure: Urinary cotinine Between group comparison of urinary total nicotine equivalents at week 20 using baseline values as a covariate. End of treatment (Week 20)
See also
  Status Clinical Trial Phase
Recruiting NCT05176418 - IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate Early Phase 1
Completed NCT04084210 - Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use Phase 2
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Withdrawn NCT03707600 - State and Trait Mediated Response to TMS in Substance Use Disorder N/A
Recruiting NCT03999099 - Targeting Orexin to Treat Nicotine Dependence Phase 1
Completed NCT03847155 - Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery N/A
Completed NCT02840435 - Study on Sit to Quit Phone Intervention N/A
Completed NCT01982110 - A Mindfulness Based Application for Smoking Cessation N/A
Completed NCT01926626 - Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers Phase 2
Completed NCT01569490 - Striving to Quit: First Breath N/A
Completed NCT01632189 - The Effect of Varenicline on D2/D3 Receptor Binding in Smokers N/A
Completed NCT01685996 - Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation Phase 1/Phase 2
Withdrawn NCT01569477 - Striving to Quit-Wisconsin Tobacco Quit Line N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT00996034 - Nicotine Vaccination and Nicotinic Receptor Occupancy Phase 2
Completed NCT01061528 - Coping Skills Treatment for Smoking Cessation N/A
Withdrawn NCT01589081 - Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect N/A
Suspended NCT01636336 - Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects N/A
Completed NCT01943994 - Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study N/A
Withdrawn NCT00571805 - Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt Phase 1/Phase 2